PODXL and familial pancreatic carcinoma: The choice of prognostic cutoff, i.e. membranous vs non-membranous PODXL expression, can be considered appropriate for the herein used antibody, since the same antibody and cutoff has been used in the previous study on pancreatic cancer by Dallas et al.[22] and since this dichotomization yielded the strongest prognostic and predictive value.